British Journal of PharmacologyPharmacology & ToxicologyPeer-reviewed journal article
Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model
Martina BonattiiD, Vanessa Pitozzi, Paola Lorenza CarusoiD, Silvia PontisiD, Maria Gloria PittelliiD, Caterina FratiiD, Denise MadedduiD, Federico QuainiiD, Costanza Anna Maria LagrastaiD, Ilaria MinatoiD, Emanuela BocchiiD, Maurizio Civelli, Gino Villetti, Marcello TrevisaniiD, Barbara MontaniniiD
Abstract
INTRODUCTIONIdiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease with a poor prognosis. While pirfenidone and nintedanib offer some benefits, they cannot cure IPF. Nintedanib inhibits various proliferative pathways and has antifibrotic effects, but its molecular mechanisms and impact on the lung transcriptome in vivo remain unclear. This study aims to evaluate nintedanibs transcriptomic profile in a rat model of bleomycin-induced lung fibrosis. METHODOLOGY/PRINCIPAL FINDINGSLung fibrosis was induced by two intratracheal administrations of bleomycin. Nintedanib protocol included three weeks of daily oral treatments beginning seven days after the first bleomycin dose. Left lungs were processed for histological evaluation using an automated fibrosis quantification system and the Ashcroft Score, while the right lungs were used for RNA sequencing to conduct differential expression and correlation network analysis (WGCNA). WGCNA modules were examined by cell and pathway enrichment analysis. Lipid peroxidation was assessed through the measurement of malondialdehyde in right lung lysates. Bleomycin induced significant fibrotic lesions, as confirmed by the histological evaluations. Nintedanib reduced fibrotic lesion size by about 15% and decreased severe Ashcroft scores. When compared to controls, the number of differentially expressed genes decreased from over 2000 to barely more than 400 after nintedanib treatment. WGCNA identified two gene clusters correlated to histological parameters, with nintedanib-treated animals showing gene expression levels similar to control animals. One cluster was associated with mesenchymal cells and extracellular matrix-related pathways, in line with the known anti-fibrotic effect of nintedanib. The second cluster, involving principally macrophages, was related to lipid metabolism, potentially uncovering a new mechanistic role of nintedanib in modulating lung fibrosis. CONCLUSIONS/SIGNIFICANCEThe mechanisms involving macrophages and lipid metabolism, influenced by nintedanib in this study, may open new research directions to better inquire the role of this cellular type in tissue repair and pathological lung fibrosis.
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 15th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis
David Lauer, C. Magnin, … Janine Gote-Schniering·JCI InsightPeer-reviewed·Jul 16, 2024
- Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis
Farida Ahangari, Christine Becker, … Gregory Paul Downey·bioRxiv·Jan 4, 2022
- Immunomodulatory nanoparticles elicit antifibrotic monocyte activation to resolve murine pulmonary fibrosis
Hannah Viola, Hannah M. Carter, … Lonnie Shea·bioRxiv·Dec 24, 2025
- A Novel CD206 Targeting Peptide Inhibits Bleomycin Induced Pulmonary Fibrosis in Mice
A. Gheberemedhin, A. B. Salam, … C. Yates·bioRxiv·Jul 27, 2020
- Targeting the Oxysterol Receptor GPR183 to Mitigate Fibrogenesis in Idiopathic Pulmonary Fibrosis
Minh Dao Ngo, Cheng Xiang Foo, … Katharina Ronacher·bioRxiv·Aug 18, 2026
- Macropinocytosis inhibition attenuates pro-fibrotic responses in lung fibroblasts and pulmonary fibrosis
Iván O. Rosas, Aaron K McDowell-Sanchez, … Konstantin Tsoyi·bioRxiv·Jul 9, 2025